To include your compound in the COVID-19 Resource Center, submit it here.

Adaptimmune rises on early promise for SPEAR TCR cell therapies in solid tumors

Cancer cell therapy play Adaptimmune gained $2.66 (200%) to $3.99 on Monday after announcing a new set of data for its SPEAR T cell therapies in four different solid tumor indications.

The announcement by Adaptimmune Therapeutics plc (NASDAQ:ADAP) at the J.P. Morgan Healthcare Conference in San Francisco disclosed four partial responses across

Read the full 526 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers